BioSpaceOriginal article
Estuary sails into kidney disease space with $103M for gene therapies
Positive
AI Analysis
Summary
Estuary Biotherapeutics raised $103M to advance two gene therapy programs targeting the root cause of autosomal dominant polycystic kidney disease, based on Yale science.
Outcome Details
Estuary Biotherapeutics raised $103M to advance two gene therapy programs for autosomal dominant polycystic kidney disease (ADPKD), based on science from Yale.
Importance:6/10
Sentiment:
0.60
gene therapyfinancingkidney diseaseADPKDYaleprivate company
Read the original article
Published by BioSpace on October 16, 2026 1:43 PM